One Day Med Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The research at One Day Med Sp. z o.o. focuses on reducing the impact of atrial fibrillation by testing new rhythm‑control agents and assessing their safety and effectiveness.
- Evaluation of AP31969 for rhythm control
- Measurement of AF burden reduction
- Assessment of patient quality of life
- Long‑term cardiovascular outcomes
The cardiology team collaborates closely with local hospitals to bring innovative treatments to patients in Szczecin.
Neoplasms
Studies at the site target advanced non‑small cell lung cancer with molecular alterations such as ALK‑positive and KRAS G12C, aiming to improve survival through targeted therapies and immunotherapy combinations.
- NVL‑655 versus alectinib in ALK‑positive NSCLC
- Olomorasib combined with pembrolizumab
- LY3537982 with platinum‑based chemotherapy
- Biomarker‑driven patient selection strategies
Oncology specialists at One Day Med Sp. z o.o. lead these trials, offering patients access to cutting‑edge cancer treatments.
Virus Diseases
The clinic is evaluating a novel topical therapy for recurrent herpes labialis, comparing its efficacy and tolerability to an established cream to shorten healing time and lower recurrence rates.
- Lipovir® Gel efficacy assessment
- Comparison with Zovirax® Cream
- Placebo‑controlled study design
- Patient‑reported symptom improvement
Residents of Szczecin interested in participating can contact One Day Med Sp. z o.o. for enrollment information.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Acesion Pharma ApS1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in One Day Med Sp. z o.o.
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Open-Label, Placebo-Controlled Trial Evaluating Aciclovir Gel Versus Aciclovir Cream in Recurrent Herpes Labialis Patients | Laboratorios Ojer Pharma S.L. | Phase III | Recruiting | Jan 2025 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Aciclovir | 1 | Unknown | 2025-01-15 | 2025-01-15 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.